Skip to main content

Effect of Alpina oxyphylla extract on streptozotocin-induced kidney injure via regulating TGF-β1 and MyD88

Abstract

Background

Abnormal renal metabolism is closely related to the development of chronic kidney disease. It is well known that renal inflammation plays an important role in the occurrence and development of tubulointerstitial damage in the renal tubules. The purpose of the experiment was to observe the bioactivity of Alpina oxyphylla extract (AOE) on renal injury in diabetic nephropathy (DN) rats induced by streptozotocin (STZ).

Methods

Thirty male Wistar rats were randomly divided into five group (n = 6): (1) intact control (non-diabetic, ND); (2) intact diabetic (STZ), (3) diabetic rats treated with gliclazide 5 mg/kg (STZ-gli), (4) diabetic rats treated with AOE 400 mg/kg (AOE 400), (5) diabetic rats treated with AOE 800 mg/kg (AOE 800). The diabetic nephropathy rat model was established by single intraperitoneal injected 50 mg/kg STZ. Fasting blood glucose (FBG) and body weight was observed at 1、3、6 weeks. After 6 weeks, the renal function parameters of five groups and 24 h urinary protein were detected. Expression of transforming growth factor-beta1 (TGF-β1) and myeloid differentiation factor 88 (MyD88) were assessed by Western Blot.

Results

The STZ group showed hyperglycemia, proteinuria, renal function damage, and the levels of 24 h urinary protein, fasting blood glucose (FBG), blood urea nitrogen (BUN), serum creatinine (Scr), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and interleukin-6 (IL-6) in the STZ group increased significantly compared with the ND group. The expression of TGF-β1 in STZ group was increase (p < 0.01), and the expression of MyD88 was significantly lower than in ND group (p < 0.05). The treatment of DN rats with AOE attenuated DN-associated in the serum biochemical index and the expression of TGF-β1.

Conclusions

AOE can effectively protect kidney tissues of diabetic nephropathy, and probably through regulating level of TGF-β1/MyD88.

Peer Review reports

Background

Diabetic nephropathy (DN) is one of the common complications of diabetes and the main cause of end stage renal disease (ESRD) [1, 2]. The clinical manifestations of DN include a complex of structure alterations, for example the hypertrophy of glomerulus and renal tubule in early stage, and glomerulosclerosis, fibrosis in late stage. The oxidative stress, inflammation reaction and metabolic abnormity in kidney were the principal reasons for the deterioration of renal function [3, 4]. The excessive reactive oxygen species (ROS) in kidney and abnormal metabolisms led to increased intracellular formation of AGEs, activation of protein kinase C isoforms, and over expressed NF-kB and TGF-β1. These increased inflammatory responses eventually result in glomerular sclerosis and renal interstitial fibrosis.

The inflammation and fibrosis were two other important factors for the development of diabetes and DN. As a cytokine closely related to renal fibrosis, the transforming growth factor β1 (TGF-β1) can active the protein kinase C (PKC) and epithelial-mesenchymal transition (EMT) in tubular epithelial cells, which ultimately contributed to the renal interstitial fibrosis [5, 6]. Furthermore, TGF-β1 can promote the glomerular and glomerular interstitial fibrosis through phosphorylating of Smad2 and Smad3 [7]. Toll like receptors (TLRs) also played an important role in development of renal inflammation [8]. TLRs could produce inflammatory cytokines through activation of NF-kB and Myeloid differentiation factor 88(MyD88), including interleukin-8 (IL-8), monocte chemotactic protein-1 (MCP-1) and interleukin-6(IL-6) [9]. In this process, MyD88 acted as an amplifier for the renal inflammation, which is vital to the deterioration of kidney [10].

The fruit of Alpina oxyphylla (A. oxyphylla) is a traditional Chinese medicine which widely distributed in the Hainan and Guangdong provinces. In Chinese medicinal practice, A. oxyphylla was mainly used to cure the polyuria caused by kidney disease [11]. In recent years, the chemical research showed that sesquiterpenoids, diterpenes, flavonoids, and diarylheptanoids were the main components of A. oxyphylla [12, 13]. The pharmacological research of A. oxyphylla indicated the AOE has antioxidant and anti-hyperglicemia bioactivities in a type II diabetic db−/db rats [14]. And the A. oxyphylla was beneficial to the renal repair in DN, this bioactivity was related to its regulating blood glucose and lipid levels and improvement of renal function [15]. However, as the important indexes of renal injury, the effects of AOE on the TGF-β1 and MyD88 remain unclear.

In order to evaluate the therapeutic effect of AOE on rat kidney injury, the STZ-induced rat diabetic model was employed to observe the bioactivities of AOE. The fasting blood glucose (FBG) concentration, 24 h urinary protein, serum creatinine (Scr), blood urea nitrogen (BUN), triglycerides (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and glutathione (GSH) were measured to evaluate the effect of AOE on renal injury. Interleukin-6 (IL-6), TGF-β1 and MyD88 were determined to explain the potential mechanisms of the therapeutic effects of AOE in DN. The research results will be helpful to explain the therapeutic mechanism of A. oxyphylla on renal injury. This research will be beneficial to clinical application of A. oxyphylla on DN.

Methods

Instruments

Electrophoresis system (041BR28093, Bio-Rad Laboratories Inc., USA); Multiskan spectrum (Max190, Molecular Devices, USA); Electronic analytical balance (XS105DU, Mettler-toledo, China); Automatic autoclave (VE-75, Systec, GER); high-speed freezing centrifuge (GTR16–2, Beijing era beili centrifuge Co., Ltd., China); Whirlpool mixer (XH-D, Shanghai Bilang Instrument Co., Ltd., China); Rotary evaporator (RE-52AA, Shanghai Yarong Biochemical Instrument Factory, China); Vacuum drying oven (DZF-6053, Shanghai Bluepard Instruments Co., Ltd., China).

Preparation of A. oxyphylla extract

The fruits of A. oxyphylla was collected from the Baisha County, Hainan Province, in June 2018 and identified by Prof. J.P. Tian (Hainan Medical University, Haikou, Hainan, China). A voucher specimen (AO-201906) was deposited at the Hainan Provincial Key Lab of R&D on Tropical Herbs. The dried and ground A. oxyphylla (1.2 kg) was extracted with 95% ethanol (2 × 12 L) under reflux for 2 h. And then the extracts were combined and concentrated in rotary evaporator. Finally, the extract was dried in a vacuum drying oven at 80 °C to obtain the AOE (102.3 g) stored in refrigerator at 4 °C for experimental usage.

Animals and induction of DN

This study was conducted in accordance with the Experimental Animal Administration regulations issue by the State Committee of Science and Technology of the People’s Republic of China. All procedures described here had prior approval from the Institutional Animal Care and Use Committee at the Hainan Medical University (Haikou, China). Male Wistar rats (230–250 g) were SPF grade, purchased from Changsha Tianqin Biotechnology Co., Ltd., all rats were housed in room temperature (23 ± 2 °C, 50–60% relative humidity) with a 12 h light 12 h / dark Cycle, Animals were given food and water for 2 days before starting the experiment. To induce DN [16] rats were given a single intraperitoneal injection of 50 mg/kg STZ (S817944-1 g, macklin, China). Three days after the injection, a blood sample was collected from the tail vein to measure the blood glucose level. The rats with a blood glucose levels exceeding 250 mg/dL (13.88 mmol/L) were considered as diabetic rats [17]. The diabetic rats were randomly divided into 5 groups (n = 6):(1) intact control (non-diabetic, ND); (2) intact diabetic (STZ), (3) diabetic rats treated with gliclazide 5 mg/kg (STZ-gli), (4) diabetic rats treated with AOE 400 mg/kg (AOE 400), (5) diabetic rats treated with AOE 800 mg/kg (AOE 800). AOE was dissolved in vehicle (10% w/v Tween-80 solution) to a concentration of 200 mg/ml. The low dose of 400 mg/kg and the high dose of 800 mg/kg were chosen according our preliminary experiments and these doses were commonly used in pharmacodynamic studies of herb’s medicines [18]. ND and STZ groups were given the same volume of distilled water. All animals were free access to standard rat diet during the experiment. At the end of 6 weeks, all rats were placed into metabolic cages for 24 h urine collection. All animals were weighed and anesthetized with intraperitoneal injection of sodium pentobarbital (50 mg/kg, Wuhan Dongkangyuan Technology Co., Ltd., China) and blood samples were collected (via femoral artery), and then the rats were sacrificed by cervical dislocation. Right kidney was weighed and rinsed with cold isotonic saline, and stored at − 80 °C before biochemical testing and Western blot analyses. The other kidney was fixed in 10% neutralized formalin for histology.

Renal histological research

The kidney tissue was fixed in 4% paraformaldehyde solution and embedded in paraffin to prepare 4 μm tissue slices. The sliced were stained with hematoxylin-eosin (HE), observed and described under an optical microscope (NIKON Eclipse ci).

Measurements of blood and 24 h urine protein

The 24 h urine collected from each rat and centrifuged at 3000 rpm for 5 min. Urinary protein concentrations were measured by Nanjing Jiancheng Bioengineering Institute kit (China). Blood samples were collected from a tail vein of the rats at 1、3、6 weeks and the Fasting blood glucose (FBG) concertration was determined using blood glucose meter (1906–05, Yuwell, China). The blood samples were centrifuged at 4 °C and 7000 rpm for 10 min to obtain the plasma samples. Serum creatinine (Scr), Blood urea nitrogen (BUN), Triglycerides (TG), Total cholesterol (TC), High density lipoprotein cholesterol (HDL-C), and Glutathione (GSH) in plasma were determined by the kits of Nanjing Jiancheng Bioengineering Institute (China), according to the manufacturer’s protocols. The level of interleukin-6 (IL-6) in rat kidney homogenate was determined by enzyme-linked immunosorbent assay (ELISA) kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).

Western blotting experiment

The renal cortex was lysed with RIPA buffer (pH 7.5) (Pierce, IL, USA). Equal amounts (30 μg) of protein were separated on a 10% SDS-PAGE (100 V, 1.5 h), and transferred to a PVDF membrane (200 mA, 40 min) under ice-cold conditions. The membrane was blocked with 5% skim milk in Tris-buffered saline containing 0.1% Tween 20 for 1 h and incubated overnight at 4 °C with the primary antibodies TGF-β1 (1:500, ab92486, Abcam, UK) and MyD88 (1:500, CN89330, Bioworld, USA). After washed with Tris-buffered saline Tween 20 (TBST) and incubated for 2 h with horseradish peroxidase (HRD) -coupled goat anti-rabbit secondary antibody. The membrane was placed on molecular Imager chemi Doc™ XRS+ imaging system (Bio-Rad) for detection. The α-Tublin was used as an internal control. The density of the bands was measured using IPP.

Statistical analysis

Results Statistical analysis was performed with SPSS 22.0 software. Data are expressed as mean standard deviation (x ± s) and statistically analyzed by Dunnett test. Values of P < 0.05 was considered to be statistically significant.

Results

Renal histological research

As shown in Fig. 1a, the morphology of renal tissue was normal in the ND group, the boundaries between renal cortex and medulla tissues were clear. Renal tubular epithelial cells were lined up tightly and no obvious inflammation was observed. While in STZ group, many cytoplasmic vacuolations and espansions of the renal tubular epithelial cell was observed, more inflammatory cell infiltration and tissue hyperplasia surrounded the renal tubule (Fig. 1b). The glomerular morphology and structure of AOE 400 and AOE 800 groups were normal, the boundaries between renal cortex and medulla tissues were clear, occasional cytoplasmic vacuolations were observed in renal tubular epithelial cells (Fig. 1d, e).

Fig. 1
figure1

Histological study of H&E staining in rat kidney sections (200× magnification). a not-diabetic group: a small amount of eosinophilic substance in the local capsular space (black arrow); b STZ-induced diabetic rats group: cytoplasmic vacuolation of renal tubular epithelium, renal tubular dilation (black arrow); c Glechide-treated drug group; d AOE treatment (800 mg/kg) group: cytoplasmic vacuolation of renal tubular epithelial cells (black arrow); e AOE treatment (400 mg/kg) group: occasionally there is a small amount of eosinophilic substance in the renal capsule (yellow arrow). cytoplasmic vacuolation of renal tubular epithelial cells (black arrow)

Effect of AOE on FBG, body and kidneys weight, and 24 h urine protein

Compared with the ND group, the urine protein level in the STZ group was significantly different (p < 0.05). Compared with the ND group, the treatment with AOE 800 and 400 groups could significantly reduce the urine protein level (p < 0.05, Table 2). The fasting blood glucose levels of the STZ group were significantly increased compared with the ND group. After treated with AOE 400 mg/kg and AOE 800 mg/kg after 6 weeks, the blood glucose decreased significantly (p < 0.05, Table 1). There was no significant difference in body weight between the groups before treatment with AOE. After 6 weeks treatment, body weight of STZ group decreased compared with ND group (P < 0.01) while the body weight of AOE treatment groups increased significantly compared with STZ group (P < 0.05). The same trend is reflected in renal weight, significant increase was also observed in AOE treatment groups compared with the STZ group (P < 0.05, Table 2).

Table 1 Average blood glucose concentration (x ± SD, mmol / L)
Table 2 Comparison of 24 h urine prtein, body weight and kidney weight (mean ± SD, n = 6)

Effect of AOE on renal function parameters

As shown in Table 3, after 6 weeks of diabetes, the levels of Scr, BUN, TG, HDL-C, and IL-6 were significantly increased in STZ group compared with the ND group. The Scr, BUN, TG, TC, HDL-C, GSH, and IL-6 in plasma of AOE 800 group significantly decreased compared with the STZ group (P < 0.01).

Table 3 Comparison of renal function parameters in rats (mean ± SD, n = 6)

Expression of TGF-β1 and MyD88 in renal tissues of rats

Compared with the ND group, the expression of TGF-β1 was up-regulated in the STZ group (p < 0.01), while the expression of MyD88 was significantly decreased (P < 0.05). After treated with AOE 800 mg/kg, the TGF-β1 level in the kidney was significant reduced, while the MyD88 level was greatly increased in Fig. 2 (P < 0.05).

Fig. 2
figure2

Effect of AOE treatment on the expression of TGF-β1, and MyD88 in renal tissue of STZ-diabetic rats. (A) normal group, (B) STZ-induced diabetic rats group, (C) Glechide-treated drug group, (D) AOE treatment (800 mg/kg) group, (E) AOE treatment (400 mg/kg) group. Compared with the ND group, *P < 0.05, **P < 0.01; Compared with the STZ group, #P < 0.05, ##P < 0.01

Discussion

This study was to evaluate the protective effect of AOE on renal injury by STZ-induced diabetic nephropathy model. Eight biochemical factors in serum and the expression of TGF-β1 and MyD88 proteins were observed to measure the biological effects of AOE on kidney. Compared with non-diabetic rats, the fasting blood glucose levels observed in STZ group were significantly higher and weight loss was observed. Administration of AOE at different dose remarkably reduced the level of blood glucose and urine protein in the STZ induced diabetic rats with improvement in the Scr, BUN, TG, TC, HDL-C, GSH, and IL-6 level.

Based on the above results, the hypoglycemic action of the A. oxyphylla may be due to the improvement glycolipid metabolism. The glucose-lipid metabolism disorder can cause local hemodynamic changes in the kidney, leading to renal interstitial fibrosis and glomerular sclerosis, which will continue to develop of DN [19, 20]. This study showed that AOE can regulate abnormal glucose lipid metabolism and prevent the occurrence of diabetes and its complications. It also further illustrates its potential clinical value in the treatment of hyperlipidemia and other fields.

The early symptoms of DN mainly manifested as microalbuminuria. The principal of pathological changes of DN included glomerulus hypertrophy, glomerulus extracellular matrix accumulating, basement membrane thickening and finally developed into glomerular sclerosis and fibrosis. In the clinic study, diabetic patients once appear persistent proteinuria symptom that will progresses to end-stage renal disease (ESRD) [20]. Therefore, DN has become an important cause of death in diabetic patients, and has important significance for the study of DN pathogenesis and prevention methods. However, due to the complexity of the cause of diabetic nephropathy, the molecular mechanisms of the occurrence of diabetic nephropathy were still unclear. The Chinese medicine A. oxyphylla is used to treat dyspepsia, diuresis, dementia, inflammation and intestinal diseases [13]. Previous studies have shown that A. oxyphylla can warm the kidney, securing essence and arresting polyuria, as well as warming the spleen and stopping diarrhea [21], other studies have shown that AOE can lower blood sugar and improve renal function in rats of DN [18].

Prevention of DN progression is a particularly challenging task. The cytokine interleukin-6 was regarded as an important role in the pathogenesis of diabetes [22, 23]. In this study, the level of IL-6 in STZ group increased significantly, after AOE treatment 6 weeks, the level of IL-6 in the kidney of the AOE treated group decreased significantly. It indicated that AOE can improve the glomerular basement membrane thickening in rats with diabetic nephropathy.

The TGF-β signaling pathway was close related to various pathological changes in the body. TGF-β is considered to be an important pathogenic factor for CKD [24]. TGF-β can reduce matrix degradation and induce podocytes, renal tubular epithelial cells and endothelial cells apoptosis in DN [25]. Renal fibrosis is associated with increased expression of TGF-β in the kidney tissue of DN, and inhibition of TGF-β of kidney has been shown to reduce fibrosis in diabetic animal models. This study showed that the expression of TGF-β1 was significantly increased in renal tissue of diabetic nephropathy. The DN rats treated with AOE 800 mg/kg significantly inhibited the up-regulation of TGF-β1, indicates that AOE may have a potential effect in reducing renal fibrosis of DN. TLR-mediated signal can lead to a variety of inflammatory factors such as IL-1, IL-6, TGF, TNF which could cause mesangial proliferation and ECM production in the kidney of DN rats [26]. It was found that AOE can improve the level of MyD88, which may be the reason why it can reduce renal inflammation.

Conclusions

In traditional Chinese medicine practice, A. oxyphylla was used as the renoprotective medicine to treat the kidney diseases. This study found that AOE could significantly improve the renal function, inhibit the IL-6 expression, lower the level of blood glucose and ameliorate renal fibrosis and inflammation. Western blot results show that AOE activated TGF and TLR signaling pathways in the kidney. These two signaling pathways could alleviate the renal fibrosis and renal tubular epithelial cells apoptosis, which resulted in the decrease of inflammatory factor production and protection of renal function. According to this research, A. oxyphylla showed a good renoprotective activity by inhibiting the renal fibrosis and inflammation. These results may provide some clues to the mechanism of the effect of A. oxyphylla on chronic renal injury.

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author of Li YH on reasonable request.

Abbreviations

AOE:

A. Oxyphylla extract

STZ:

Streptozotocin

FBG:

Fasting blood glucose

DN:

Diabetic nephropathy

ECM:

Extracellular matrix

TC:

Total cholesterol

TG:

Triglycerides

HDL-C:

High density lipoprotein cholesterol

BUN:

Blood urea nitrogen

Scr:

Serum creatinine

GSH:

Glutathione

IL-6:

Interleukin-6

TGF-β:

Transforming growth factor-beta

MyD88:

Myeloid differentiation factor 88

References

  1. 1.

    Boer D, Ian H, Tessa C, Yoshio N, Patrick J, Noel S, Drph JH. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–9.

    PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci. 2013;124(3):139–52.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Wu H, Kong L, Zhou S, Cui W, Xu F, Luo M, Li X, Tan Y, Miao L. The role of microRNAs in diabetic nephropathy. J Diabetes Res. 2014;4:1–12.

    CAS  Google Scholar 

  4. 4.

    Desirée LR, Alberto MC, José LG, Álvaro F, Juan F. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J Diabetes. 2012;3(1):7–18.

    Article  Google Scholar 

  5. 5.

    Yu R, Mao J, Yang Y, Zhang Y, Tian Y, Zhu J. Protective effects of calcitriol on diabetic nephropathy are mediated by down regulation of TGF-β1 and CIP4 in diabetic nephropathy rat. Int J Clin Exp Pathol. 2014;8(4):3503–12.

    Google Scholar 

  6. 6.

    Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci. 2000;97(14):7667–9.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Gao F, He X, Liang S, Liu S, Liu H, He Q, Chen L, Jiang H, Zhang Y. Quercetin ameliorates podocyte injury via inhibition of oxidative stress and the TGF-1/Smad pathway in DN rats. RSC Adv. 2018;8:35413–21.

    CAS  Article  Google Scholar 

  8. 8.

    Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA. TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. Cytokine. 2017;89:127–35.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Yokoyama T, Komori A, Nakamura M, Takii Y, Kamihira T, Shimoda S, Mori T, Fujiwara S, Koyabu M, Taniguchi K, Fujioka H, Migita K, Yatsuhashi H, Ishibashi H. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-κB and -MAPK signaling pathways. Liver Int. 2006;26(4):467–76.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Liu P, Li F’a, Qiu M, He L. Expression and cellular distribution of TLR4, MyD88, and NF-κB in diabetic renal tubulointerstitial fibrosis, in vitro and in vivo. Diabetes Res Clin Pract. 2014;105(2):206–16.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Li YH, Tan YF, Wei N, Zhang JQ. Diuretic and anti-diuretic bioactivity differences of the seed and shell extracts of alpinia oxyphylla fruit. Afr J Tradit Complem. 2016;13(5):25–32.

    CAS  Google Scholar 

  12. 12.

    Xie YQ, Xiao M, Li D, Liu HG, Yun FL, Wei Y, Sang SG, Du GK. Anti-diabetic effect of alpinia oxyphylla extract on 57BL/KsJ db−/db- mice. Exp Ther Med. 2017;13(4):1321–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Wang S, Zhao Y, Zhang J, Huang X, Wang Y, Xu X, Zheng B, Zhou X, Tian H, Liu L, Mei Q. Antidiarrheal effect of alpinia oxyphylla Miq. (Zingiberaceae) in experimental mice and its possible mechanism of action. J Ethnopharmacol. 2015;168:182–90.

    PubMed  Article  Google Scholar 

  14. 14.

    Du G, Xiao M, Zhang X, Wen M, Pang C, Jiang S, Sang S, Xie Y. Alpinia oxyphylla Miq. extract changes miRNA expression profiles in db−/db- mouse kidney. Biol Res. 2017;50(1):1–9.

    Article  Google Scholar 

  15. 15.

    Kim EJ, Lee YJ, Ahn YM, Lee H, Kang DG, Lee HS. Renoprotective effect of alpiniae oxyphyllae fructus on ischemia/reperfusion-induced acute renal failure. Arch Pharm Res. 2013;36(8):1004–12.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy (methods in renal research). Nephrology. 2007;12(3):261–6.

    PubMed  Article  Google Scholar 

  17. 17.

    Rajesh KS, Ipseeta RM, Manjusha KB, Ujwala M, Deshmukh YA. Development of an experimental model of diabetes co-existing with metabolic syndrome in rats. Adv Pharmacol Sci. 2015;2016:1–11.

    Google Scholar 

  18. 18.

    Xie Y, Xiao M, Ni Y, Jiang S, Feng G, Sang S, Du G. Alpinia oxyphylla, Miq. extract prevents diabetes in mice by modulating gut microbiota. J Diabetes Res. 2018. https://doi.org/10.1155/2018/4230590.

  19. 19.

    Zhao YY, Vaziri ND, Lin RC. Lipidomics: new insight into kidney disease. Adv Clin Chem. 2015;68:153–75.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Jha V, Garcia-Garcia G, Iseki K, Naicker S, Plattner B, Saran R, Wang YM. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72.

    PubMed  Article  Google Scholar 

  21. 21.

    Zhang Q, Zheng Y, Hu X, Lv W, Lv D, Chen J, Wu M, Song Q, Shentu J. Ethnopharmacological uses, phytochemistry, biological activities, and therapeutic applications of, Alpinia oxyphylla, Miquel: a review. J Ethnopharmacol. 2018;224:149–68.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Zhang C, Xiao C, Wang P, Xu W, Zhang A, Li Q, Xu X. The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Hum Immunol. 2014;75(4):289–96.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Wu R, Liu X, Yin J, Wu H, Cai X, Wang N, Qian Y, Wang F. IL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in mice. Metabolism. 2018;6:S18–24.

    Article  Google Scholar 

  24. 24.

    Liu Q, Jiao X, Chen B, Zhao W, Meng D. The role of TGF-β1, P53 and microRNA 192 in the pathogenesis of diabetic nephropathy in diabetic rats. Int J Clin Exp Med. 2016;9(2):3139–45.

    CAS  Google Scholar 

  25. 25.

    Ziyadeh FN. Mediators of diabetic renal disease: The case for TGF-β as the major mediator. J Am Soc Nephrol. 2003;15:S55–7.

  26. 26.

    Tang Y, Zhou G, Yao L, Xue P, Yu D, Xu R, Shi W, Yao X, Yan Z, Duan JA. Protective effect of Ginkgo bilobaleaves extract, EGb761, on myocardium injury in ischemia reperfusion ratsviaregulation of TLR-4/NF-κB signaling pathway. Oncotarget. 2017;8(49):86671–80.

    PubMed  PubMed Central  Article  Google Scholar 

Download references

Acknowledgements

Not Applicable.

Funding

This work was supported by the National Natural Science Foundation of China (Nos. 81560738). The funding body have not involved in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author information

Affiliations

Authors

Contributions

WJX conducted the experiment and manuscript writing. YHL designs experiments and corrects the manuscript for publication. YFT and YW participate in animal experiments. JPT participated in the identification of Chinese medicines. HX and BMG analyze experimental data. HIL conducts experiments and analyzes data. AJ guides work and evaluates experimental data. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yong-hui Li.

Ethics declarations

Ethics approval and consent to participate

All the animal experiments was conducted in accordance with the Experimental Animal Administration regulations issue by the State Committee of Science and Technology of the People’s Republic of China and prior approval from the Institutional Animal Care and Use Committee at the Hainan Medical University (Haikou, China).

Consent for publication

Not Applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wu, J., Jia, A., Tan, Y. et al. Effect of Alpina oxyphylla extract on streptozotocin-induced kidney injure via regulating TGF-β1 and MyD88. BMC Complement Med Ther 20, 217 (2020). https://doi.org/10.1186/s12906-020-02972-x

Download citation

Keywords

  • Alpina oxyphylla
  • Diabetic nephropathy
  • TGF-β1
  • MyD88